IonGate Biosciences and LIVC Technologies Establish Technology and Marketing Co-operation
News Sep 05, 2007
IonGate Biosciences GmbH and LIVC Technologies GmbH have announced a co-operation for joint development and marketing of the LIVC Technology.
LIVC is a proprietary technology that can initiate and measure voltage activated ion channels via light induction, which works similar to a remote control.
Until now, high-throughput activation and exploration of ion channels has only been possible in low quality. The so-called LIVC Technology (Light Induced Voltage Clamp) finally allows high-throughput screening of voltage activated ion channels without any loss of time or information.
Firstly, a light activated ion channel is entered into the target cells. Secondly, this ion channel is then opened via a light impulse. The activation of the ion channel leads to depolarization in turn activates the ion channels which are the targets of exploration. With LIVC, it is possible to switch on and off voltage activated ion channels under physiological conditions. Thus, the function of these ion channels in a living organism can be imitated.
The high potential of the LIVC Technology lies in the improvement of research methods in the pharmaceutical industry, for finding new, or optimizing existing, compounds that act directly on the voltage activated ion channels. With LIVC, pharmaceutical companies will be able for the first time to get high-quality information in high-throughput information on new drug candidates and their method of action.
However, the perspectives for LIVC in pharmaceutical research far exceed the high-throughput screening of new compounds. For example, scientists could study the complex network of neurons in the brain and thus can improve the diagnosis of diseases of the central nervous system.
IonGate Biosciences and LIVC Technologies have agreed to co-operate in the area of international marketing of the LIVC Technology. Further details of the agreement will be published at a later date.
IonGate will present the new technology to an international audience during the "Screening Targets & Ion Channel Targets" conference in Boston, USA, which will be held on the 10th and 11th of September 2007.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE